<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Examples of impact and cost-effectiveness models developed for hepatitis B elimination</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Country Context</th>
    <th>Analysis type</th>
    <th>Outcome</th>
    <th>Factors with greatest impact on impact and costs</th>
    <th>Authors</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Global Model</td>
    <td>Simulation dynamic deterministic state transition model and costing model to estimate total costs of interventions</td>
    <td>Impact on new infections and mortality, comparing status quo versus achieving 2015 SDGs for HIV, tuberculosis and malaria applied to hepatitis B</td>
    <td>1. Scale-up infant vaccination coverage
     <break/>2. Scale-up birth dose vaccination coverage
     <break/>3. Effectiveness of vaccination
     <break/>4. Use of peripartum tenofovir
     <break/>5. Population-wide testing and treatment
     <break/>6. Adherence to treatment
    </td>
    <td>Nayagam S et al (2016)(15)</td>
   </tr>
   <tr>
    <td>Global Model focused on 67 low and middle income countries</td>
    <td>WHO SDG investment model extended to include costs for hepatitis B</td>
    <td>Health impact (deaths averted, health lives gained) and cost of scale-up of existing HBV testing and treatment programs to achieve WHO 2030 elimination targets</td>
    <td>1.Diagnostics
     <break/>2. Staff costs
    </td>
    <td>Tordrup et al (2019)(37)</td>
   </tr>
   <tr>
    <td>Global</td>
    <td>Cost-effectiveness analysis using a Markov state transition model</td>
    <td>1.Cost-effectiveness of use of HBV vaccine outside of cold chain (controlled temperature chain)
     <break/>2.HBV-related DALYs averted
    </td>
    <td>1.HBV prevalence
     <break/>2.Proportion timely birth dose delivered
    </td>
    <td>Scott N et al (2018) (
     <xref rid="bib56" ref-type="bibr">56</xref>)
    </td>
   </tr>
   <tr>
    <td>Australia</td>
    <td>Cost-effectiveness analysis using a Markov state transition model (healthcare system perspective)</td>
    <td>1.Cost-effectiveness of upscaling current programs to achieve WHO elimination targets by 2030
     <break/>2.Total cost of implementation programs to achieve WHO targets and remain under the cost-effectiveness threshold
    </td>
    <td>1.Drug costs
     <break/>2.Disease progression rates (eg: impact of treatment, timing of treatment)
    </td>
    <td>Xiao Y et al (2019)(38)</td>
   </tr>
   <tr>
    <td>Cambodia</td>
    <td>Cost-effectiveness analysis using decision tree modelling based on existing Regional Framework for Triple Elimination of Mother to Child Transmission of HIV, HBV and syphilis in Asia and the Pacific 2018-2030</td>
    <td>Impact on mother-to-child transmission and cost-effectiveness of integration of HBV prevention (antenatal testing, birth dose vaccination, HBIg, +/- tenofovir)</td>
    <td>1.Drug cost
     <break/>2.HBIg cost and procurement
    </td>
    <td>Zhang L et al (2019)(42)</td>
   </tr>
   <tr>
    <td>China</td>
    <td>Cost and health impact analysis using a dynamic Markov state transition model</td>
    <td>1.Health impact of upscaled comprehensive hepatitis B elimination package
     <break/>2.Cost of package to achieve elimination targets
     <break/>3.Return on investment of comprehensive elimination package
     <break/>4.Co-financing strategies simulation
    </td>
    <td>1.Diagnostics
     <break/>2.Drug costs
     <break/>3.Financing model (eg public-private partnerships from societal perspective)
    </td>
    <td>Nayagam S et al (2016)(36)</td>
   </tr>
   <tr>
    <td>South Korea</td>
    <td>Cost-effectiveness analysis using Markov state transition model</td>
    <td>Cost-effectiveness of standard birth dose vaccine and HBIg compared with additional antiviral therapy in third trimester for perinatal prevention of mother-to-child transmission</td>
    <td>1.Drug costs
     <break/>2.Prevalence maternal high viral load
    </td>
    <td>Lee D et al (2018)(89)</td>
   </tr>
   <tr>
    <td>The Gambia</td>
    <td>Cost-effectiveness analysis using a Markov state transition model</td>
    <td>Community-based screening and treatment</td>
    <td>1. Drug cost
     <break/>2. Diagnostics cost
     <break/>3. Targeted facility-based screening
     <break/>4. Integration into existing services to reduce staff costs
    </td>
    <td>Nayagam S et al. (2016)(33)</td>
   </tr>
   <tr>
    <td>Senegal</td>
    <td>Cost and health impact analysis using a Markov state transition model adapted from The Gambia</td>
    <td>1. Health impact towards achieving WHO 2030 targets of gradual and rapid (twice gradual) up-scale testing and treatment scenario
     <break/>2.Costs of programs- including breakdown of costs of individual elimination activities in Senegal
     <break/>3.Financing gap compared with current National Strategic Plan and modelled strategies to reduce costs
    </td>
    <td>1.Diagnostics cost
     <break/>2.Drug cost
    </td>
    <td>Ministry of Health and Sport (2019)(86)</td>
   </tr>
   <tr>
    <td>South Africa</td>
    <td>Cost model and dynamic deterministic state transition model</td>
    <td>Health Impact and cost-effectiveness of birth dose vaccination, prevention mother-to-child transmission and HBV treatment</td>
    <td>Using prevention of mother-to-child transmission programs to source cases for HBV treatment</td>
    <td>Hecht R et al (2018)(11)</td>
   </tr>
   <tr>
    <td>Netherlands</td>
    <td>Cost-effectiveness analysis using a Markov state transition model</td>
    <td>Cost-effectiveness of migrant hepatitis B and C screening program for all migrants from high prevalence areas in a low prevalence country</td>
    <td>1.Drug costs (in high income country)
     <break/>2.Prevalence in migrant target population
     <break/>3.Cost-effective when HBV and HCV combined screening
    </td>
    <td>Suijkerbuijk AWM et al (2018)(90)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
